Pfizer’s once-a-week hemophilia antibody reduces bleeding in PhIII study
30 May 2023
Phase 3Clinical Result
Pfizer’s once-a-week antibody treatment for hemophilia A and B helped reduce bleeding events in patients compared to their usual treatment of blood clotting factor infusions, the pharma company announced Tuesday morning.
The open-label Phase III study included 116 people with hemophilia who were first treated for six months with either regular or on-demand infusions of factor VIII or IX — the clotting factors that patients with hemophilia A and B are missing. Then, both groups switched over to once-a-week treatment with Pfizer’s antibody marstacimab for one year.
Preview
Source: EndPoints
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.